Peripheral Avascular Retina in Retinopathy of Prematurity

Launched by ASSIUT UNIVERSITY · Sep 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a condition called retinopathy of prematurity (ROP), which affects the eyes of preterm infants and can lead to vision problems or blindness. The researchers want to learn more about a specific issue known as persistent avascular retina (PAR), where parts of the retina do not develop normally. They are using advanced imaging technology to better detect and understand these problems in children who have had ROP.

If your child is between 18 months and 2 years old and has been diagnosed with persistent peripheral avascular retina, they might be eligible to participate in this study. Qualifying children include those who have had ROP that improved on its own without treatment, as well as those who received specific injections for ROP. Participants will undergo follow-up assessments to monitor their eye health and vision. It's important to know that children who have had certain treatments or other eye problems may not be able to join the trial. This research aims to improve our understanding of ROP and potentially lead to better outcomes for affected children.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with persistent peripheral avascular retina attending follow up till the age of 18 months in the core study whether;
• • regressed ROP: children with regressed ROP who had not received any treatment.
• • IVI treatment ROP: children with a history of threshold ROP treated with IVI of anti-VEGF agents.
• Exclusion Criteria:
• • Eyes with previous laser therapy.
• • Eyes with any other pathology, other than ROP.
• • Eyes with stage 4 or 5 ROP.
• • Patients with hypersensitivity to iodinated contrast media, liver and renal insufficiency, history of asthma.
• • Patients who will show hypersensitivity reaction to fluorescein angiography will be excluded from the thesis.
• • Patients unfit for general anesthesia.